Development of an adenoviral vector with robust expression driven by p53

Virology

Volumn 371, Issue 1, 2008, Pages 8-13

  Bajgelman, Marcio C ^a,b,c   Strauss, Bryan E ^a,b,c  

^a Heart Institute (InCor)   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MCT   (Brazil)

Author keywords

Adenovirus; Doxorubicin; Gene therapy; p53; Prostate carcinoma; Taxol

Indexed keywords

ADENOVIRUS VECTOR; BETA GLOBIN; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENHANCER ELEMENTS (GENETICS); GENE THERAPY; GENES, P53; GENES, REPORTER; GENETIC VECTORS; HUMANS; INTRONS; LUCIFERASES; MALE; PACLITAXEL; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RABBITS; TRANSDUCTION, GENETIC; TRANSFECTION; TRANSGENES;

ADENOVIRIDAE; ORYCTOLAGUS CUNICULUS;

EID: 37849037082     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.11.015     Document Type: Article

References (25)

1. Bajgelman M.C., and Strauss B.E. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Prostate 66 13 (2006) 1455-1462
2. Bajgelman M.C., Costanzi-Strauss E., and Strauss B.E. Exploration of critical parameters for transient retrovirus production. J. Biotechnol. 103 2 (2003) 97-106
3. Bonadonna G., and Monfardini S. Cardiac toxicity of daunorubicin. Lancet vol. 1 (1969) 837
4. Burns J.C., Friedmann T., Driever W., Burrascano M., and Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8033-8037
5. Ingram N., and Porter C.D. Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy. Gene Ther. 12 (2005) 1058-1069
6. Kern S.E., Pietenpol J.A., Thiagalingam S., Seymour A., Kinzler K.W., and Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256 5058 (1992) 827-830
7. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev. 10 (1996) 1054-1072
8. Kurz E.U., Douglas P., and Lees-Miller S.P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 279 (2004) 53272-53281
9. Latham J.P., Searle P.F., Mautner V., and James N.D. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 60 (2000) 334-341
10. Liu X.Y., Gu J.F., and Shi W.F. Targeting gene-virotherapy for cancer. Acta Biochim. Biophys. Sin. (Shanghai) 37 (2005) 581-587
11. Michalovitz D., Halevy O., and Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62 (1990) 671-680
12. Mizuguchi H., and Hayakawa T. The tet-off system is more effective than the tet-on system for regulating transgene expression in a single adenovirus vector. J. Gene Med. 4 (2002) 240-247
13. Nielsen L.L., Lipari P., Dell J., Gurnani M., and Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4 (1998) 835-846
14. Nishizaki M., Meyn R.E., Levy L.B., Atkinson E.N., White R.A., Roth J.A., and Ji L. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin. Cancer Res. 7 (2001) 2887-2897
15. Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., and Runnebaum I.B. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther. 11 (2004) 547-554
16. Resnick-Silverman L., and Manfredi J.J. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J. Cell. Biochem. 99 (2006) 679-689
17. Schambach A., Wodrich H., Hildinger M., Bohne J., Krausslich H.G., and Baum C. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Molec. Ther. 2 (2000) 435-445
18. Shiraishi K., Kato S., Han S.Y., Liu W., Otsuka K., Sakayori M., Ishida T., Takeda M., Kanamaru R., Ohuchi N., and Ishioka C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J. Biol. Chem. 279 1 (2004) 348-355
19. Strano S., Dell'Orso S., Di Agostino S., Fontemaggi G., Sacchi A., and Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene 26 (2007) 2212-2219
20. Strauss B.E., and Costanzi-Strauss E. pCLPG: a p53-driven retroviral system. Virology 321 (2004) 165-172
21. Strauss B.E., Bajgelman M.C., and Costanzi-Strauss E. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Ther. 12 (2005) 935-946
22. Wu L., Matherly J., Smallwood A., Adams J.Y., Billick E., Belldegrun A., and Carey M. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 8 (2001) 1416-1426
23. Xavier-Neto J., Pereira A.C., Motoyama A.H., and Krieger J.E. A luciferase-engineered cell line for study of cAMP regulation in endothelial cells. Am. J. Physiol. 275 (1998) C75-C81
24. Yoshimura I., Suzuki S., Tadakuma T., and Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int. J. Urol. 8 (2001) S5-S8
25. Zhang W., Guo X.Y., Hu G.Y., Liu W.B., Shay J.W., and Deisseroth A.B. A temperature-sensitive mutant of human p53. EMBO J. 13 11 (1994) 2535-2544